The Food and Drug Administration has quietly stopped advancing its Commissioner's National Priority Voucher program, which promised drug decisions within one to two months instead of the usual 10 to 12, Reuters reported Nov. 12, citing sources. FDA leadership has told companies the program is not moving forward, though applications technically remain open, according to Pharmaceutical Technology's summary of the report.
The Department of Health and Human Services disputes that framing. HHS and FDA spokesperson Emily Hilliard said the pilot is ongoing and that the agency is reviewing feedback from a June public hearing to refine it.